WATCH NOW
Larimar Therapeutics Webinar | March 20, 2026
On March 20, 2026, Russell Clayton, DO, Chief Medical Officer at Larimar Therapeutics, shared updates about the nomlabofusp clinical program including information about opportunities for children, adolescents, and adults to enroll in the open label study as well as the upcoming phase 3 study.
